セッション詳細
[S-33]シンポジウム33 Incretin-related drugs: a possible panacea?
2025年5月23日(金) 15:00 〜 17:00
第01会場(大阪国際会議場5F 大ホール)
座長：磯部 紀子（九州大学大学院医学研究院 神経内科学）, 木村 康義（大阪大学大学院医学系研究科 神経内科・脳卒中科）
Incretin hormones, which include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are gut peptides secreted upon nutrient intake. As incretin lowers blood glucose levels and decreases appetite, incretin mimetics are now marketed for the treatment of diabetes and obesity. Of note, incretin binds to its G-protein coupled receptor and transduces multiple signals which enhance cellular survival and modulate inflammatory responses. Based on this molecular biological action, incretin-related drugs such as GLP-1 receptor agonists have recently attracted attention for their potential as "panaceas" for many chronic conditions, including neurological disorders. In this symposium, leading researchers will give a talk and discussion about incretin mimetics and their potential applications, particularly in Parkinson's disease and Alzheimer's diseases.
[S-33-1]糖尿病・肥満症治療のためのインクレチン関連製剤
下村 伊一郎 (大阪大学大学院医学系研究科 内分泌・代謝内科学)
Education and position:
1989: Faculty of Medicine, Osaka University (M.D.)
1993: Osaka University Graduate School of Medicine (Ph.D.) (Dr. Yuji Matsuzawa)
1995-2001: University of Texas, Southwestern Medical Center at Dallas (Drs. Joseph L Goldstein and Michael S Brown). 1995-1997: Postdoctoral fellow, 1997-1999: Instructor, 1999-2001: Assistant Professor
2002-2004: Professor, Department of Medicine and Pathophysiology, Graduate School of Medicine, Graduate School of Frontier Bioscience, Osaka University.
2004-present: Professor and Chairman, Department of Internal Medicine and Metabolic Medicine, Graduate School of Medicine, Osaka University.
DIRECTOR OF SCIENTIFIC SOCIETY
Vice Chairman and Director of the Japan Society for the Study of Obesity
Director of the Japan Diabetes Society
Director of Japan Endocrinology Society
Director of Japanese Society of Molecular Medicine
1989: Faculty of Medicine, Osaka University (M.D.)
1993: Osaka University Graduate School of Medicine (Ph.D.) (Dr. Yuji Matsuzawa)
1995-2001: University of Texas, Southwestern Medical Center at Dallas (Drs. Joseph L Goldstein and Michael S Brown). 1995-1997: Postdoctoral fellow, 1997-1999: Instructor, 1999-2001: Assistant Professor
2002-2004: Professor, Department of Medicine and Pathophysiology, Graduate School of Medicine, Graduate School of Frontier Bioscience, Osaka University.
2004-present: Professor and Chairman, Department of Internal Medicine and Metabolic Medicine, Graduate School of Medicine, Osaka University.
DIRECTOR OF SCIENTIFIC SOCIETY
Vice Chairman and Director of the Japan Society for the Study of Obesity
Director of the Japan Diabetes Society
Director of Japan Endocrinology Society
Director of Japanese Society of Molecular Medicine
[S-33-2]GLP-1受容体作動薬のドラッグリポジショニング
木村 康義 (大阪大学大学院医学系研究科 神経内科学)
Dr. Yasuyoshi Kimura is an assistant professor in the Department of Neurology, Graduate School of Medicine, the University of Osaka. He received his M.D. from the University of Osaka in 2008. He completed a residency in clinical neurology at the Higashiosaka City Medical Center and Osaka University Hospital. After obtaining his Ph.D. degree from the University of Osaka in 2016, he worked as an assistant professor there. From 2017 to 2019, he worked as a postdoctoral research fellow at the Institute for Cell Engineering, Johns Hopkins University School of Medicine, USA. He became a specially appointed assistant professor (from 2020) and an assistant professor (from 2021) in the Department of Neurology, the University of Osaka. His current research interests include neurodegenerative disorders especially alpha-synucleinopathy and development of treatments.
[S-33-3]アルツハイマー病の治療におけるGLP1受容体アゴニストの可能性
池内 健 (新潟大学脳研究所 生命科学リソース研究センター)
1991 Graduated from Niigata University School of Medicine
1993 Resident, Neurology, Niigata University Hospital
2000 Ph.D. from Niigata University Graduate School of Medicine
2000 Postdoctral fellow, The University of Chicago
2004 Assistant Professor, Neurology, Niigata University Hospital
2005 Assistant Professor, Brain Research Institute, Niigata University
2007 Program officer, MEXT
2011 Associate Professor, Center for Transdisciplinary Research, Niigata University
2013 Professor, Brain Research Institute, Niigata University (current position)
2020 Director, Medical Genetics Center, Niigata University Medical and Dental Hospital (current position)
1993 Resident, Neurology, Niigata University Hospital
2000 Ph.D. from Niigata University Graduate School of Medicine
2000 Postdoctral fellow, The University of Chicago
2004 Assistant Professor, Neurology, Niigata University Hospital
2005 Assistant Professor, Brain Research Institute, Niigata University
2007 Program officer, MEXT
2011 Associate Professor, Center for Transdisciplinary Research, Niigata University
2013 Professor, Brain Research Institute, Niigata University (current position)
2020 Director, Medical Genetics Center, Niigata University Medical and Dental Hospital (current position)
[S-33-4]The LIXIPARK trial: lixisenatide to treat patients with early Parkinson disease (PD)
Olivier Rascol1,2,3 (1.Neursociences and Clinical Pharmacology at Toulouse University Hospital, 2.Clinical Pharmacology at University of Toulouse, 3.Clinical Investigation Center INSERM)
Doctor Olivier Rascol is a neurologist specialized in Movement Disorders, Professor of Clinical Pharmacology at Toulouse University Hospital. Dr Rascol is running Toulouse Clinical Investigation Centre (CIC14136) since 1994 and Toulouse Space Clinic since 1998. He is coordinator of Toulouse Expert Center for Parkinson Disease (PD) and of the national French Reference Center for Multiple System Atrophy (MSA). Dr Rascol is the chair of the NS-Park/F-CRIN Network on clinical research in PD since 2010 and of the National French Clinical Research Infrastructure Network F-CRIN.
As a clinical neuropharmacologist, Pr Rascol’s main fields of interest are clinical trials, biomarkers and pharmaco-epidemiology of PD, MSA and other movement disorders. Pr Rascol has been involved in the development of most marketed antiparkinsonian medications within the last 30 years. He is currently running several trials for disease progression (neuroprotection) or symptomatic management of PD and MSA in collaboration with national and international academic and industry partners. Pr Rascol is a scientific advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies.
Pr Rascol has been invited worldwide to give more than 550 lectures in Europe, North America, South America and Asia, and published 600 articles in international scientific journals.
As a clinical neuropharmacologist, Pr Rascol’s main fields of interest are clinical trials, biomarkers and pharmaco-epidemiology of PD, MSA and other movement disorders. Pr Rascol has been involved in the development of most marketed antiparkinsonian medications within the last 30 years. He is currently running several trials for disease progression (neuroprotection) or symptomatic management of PD and MSA in collaboration with national and international academic and industry partners. Pr Rascol is a scientific advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies.
Pr Rascol has been invited worldwide to give more than 550 lectures in Europe, North America, South America and Asia, and published 600 articles in international scientific journals.